Mallinckrodt to unveil first clinical data on MNK-795 Mallinckrodt announced that the first clinical data on MNK-795 will be presented at PAINWeek 2013, to be held September 4-7 in Las Vegas. MNK-795 is an extended-release oral formulation of oxycodone and acetaminophen that has been studied in clinical trials for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate. On July 29, Mallinckrodt announced that the U.S. Food and Drug Administration accepted for filing the New Drug Application for MNK-795 and granted priority review. The data to be presented include results from a human abuse liability study comparing certain abuse-related characteristics of intact and tampered with MNK-795 with that of intact and tampered with Percocet.
News For MNK From The Last 14 Days
Check below for free stories on MNK the last two weeks.